Negative Pressure Wound Therapy as a Drug Delivery System (ADANPWT) (ADA NPWT)
Primary Purpose
Foot Ulcer, Diabetic
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Quantum™ Therapy - NPWT with Prontosan
Quantum™ Therapy
Sponsored by
About this trial
This is an interventional treatment trial for Foot Ulcer, Diabetic focused on measuring diabetic foot ulcer
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of diabetes mellitus
- Men/women ≥21 years old
- Foot or ankle wounds sized 5 cm2 -100 cm2
- ABI≥0.5 or toe pressures >30 mmHg
Exclusion Criteria:
- Active Charcot arthropathy
- Unable to use NPWT at home
- Untreated bone or soft tissue infection
- Unable to keep research appointments
- Active alcohol or substance abuse (> 14 drinks per week over the last 3 months) or substance abuse (current use of cocaine, heroine or methamphetamine or if drug or alcohol use will interfere with follow up visits in foot clinic in the opinion of the investigator)
Sites / Locations
- UT Southwestern Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Quantum™ Therapy/NPWT with Prontosan
Quantum™ Therapy
Arm Description
Quantum™ Negative Pressure Wound Therapy with Prontosan irrigant.
Quantum™ Negative Pressure Wound Therapy without irrigant.
Outcomes
Primary Outcome Measures
Compare clinical outcomes (time to wound healing, number of surgeries) with Negative Pressure Wound Therapy with irrigation and Negative Pressure Wound Therapy without irrigation.
The investigators expect that patients treated with NPWT with irrigation will a have higher proportions of wounds that heal, fewer surgeries, and faster wound healing trajectories when compared to patients treated with traditional NPWT without irrigation.
Secondary Outcome Measures
Compare quantitative cultures (bacterial load as measured by qPCR) and number of clinical infections in patients treated with NPWT with irrigation compared to conventional NPWT.
The investigators expect that patients treated with NPWT and irrigation will have a significantly lower bacterial load, and fewer and less severe clinical infections.
Full Information
NCT ID
NCT02308800
First Posted
November 7, 2014
Last Updated
January 17, 2019
Sponsor
University of Texas Southwestern Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02308800
Brief Title
Negative Pressure Wound Therapy as a Drug Delivery System (ADANPWT)
Acronym
ADA NPWT
Official Title
Negative Pressure Wound Therapy as a Drug Delivery System
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Withdrawn
Study Start Date
January 2015 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Texas Southwestern Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The investigators plan a randomized clinical trial of 150 patients with infected diabetes-related lower extremity wounds to compare the clinical and economic effectiveness of negative pressure wound therapy with continuous irrigation and negative pressure wound therapy without irrigation.
The investigators will enroll 150 patients from two centers: The University of Texas Southwestern University Hospital and Parkland Hospital. The investigators will screen and enroll patients with wounds in the inpatient setting. Patients will randomized to receive traditional NPWT or NPWT with continuous irrigation while they are hospitalized. The average hospitalization for patents that receive NPWT is 13.3 days. Patients that do not have their wound surgically closed during hospitalization will be discharged with negative pressure wound therapy without irrigation for up to a total of four weeks of therapy. After discharge from the hospital, subjects will be seen twice weekly by home health, and the investigators will evaluate subjects in clinic every 7 days (±7 days) for a total of 16-week period or until the wound heals.
Detailed Description
Screening Procedures
Review and sign the Informed Consent and HIPAA Authorization
The study doctor will review the inclusion and exclusion criteria
Demographics (such as age, gender, race or ethnicity)
Sitting blood pressure and pulse at admission
Collection of Height and weight at admission
Collection of the medical and surgical history
Collection of the history of the wound
Wound assessment(s) - wound etiology, wound history, location of study wound and infection assessment
Hyperspectral imaging within 30 days of screening
Vascular/Neurological evaluation - we will do various tests and measurements to assess the sensation (feeling) and circulation (blood flow) in the subject's feet and lower legs. To assess the sensation, we will do a monofilament sensory test and a vibration threshold perception test on the study foot. We will calculate the neuropathy disability score of both feet. To assess circulation, we will record Skin Perfusion Pressures in the study foot using a Sensilase System (Vasamed, Eden Prairie, MN) within 30 days of screening. We will calculate the ankle brachial index (ABI) at screening and collect available arterial doppler data from the medical record within 6 months of screening. None of these tests are invasive (using needles), uncomfortable or have risks greater than standard care.
Results of standard-of-care laboratory tests including a white blood cell count, blood chemistry (tests to see how well organs, such as the liver and kidneys are working), glycated hemoglobin, albumin, prealbumin, erythrocyte sedimentation rate, C-reactive protein and blood glucose. Results of a serum pregnancy test (standard care for women of child-bearing potential as part of pre-op labs) will also be collected. Collection of a list of the subject's current antibiotics
We will provide the SF-36 Questionnaire and other patient-reported outcomes questionnaires and collect them while subjects are inpatient.
This visit will last about 2 hours.
If you qualify for the study, you will participate in the following procedures:
Group Assignment
If the researchers believe the subject can take part in this study, s/he will be assigned randomly (like a flip of a coin) to receive one of the following therapies:
Negative Pressure Wound Therapy with Irrigation
Negative Pressure Wound Therapy without Irrigation
The group is assigned randomly (like flipping a coin). The sponsor or researchers do not know in advance what group assignment each subject will receive. Neither the subject nor the researchers will be allowed to choose which group s/he is assigned to.
Study Intervention
The subject will receive either:
Quantum™+Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan®, or
Quantum™(NPWT) -Negative Pressure Wound Therapy (without Prontosan®)
Assigned therapy will continue in the hospital until the physician determines that the wound is ready for closure. If the subject's wound is healing, study therapy will be discontinued and standard dressings will be applied. If surgical closure is needed, the subject will return to the Operating Room for a procedure to close the wound.
If the wound is not ready for closure during the hospital stay, subjects will continue NPWT at home. NPWT at home will be without irrigation.
Procedures and Evaluations during the Research The study therapy will only be given while the subject is in the hospital. If the subject's wound is not ready for closure during the hospital stay, the subject will continue NPWT at home. NPWT at home will be without irrigation. Once the therapy is stopped s/he will continue to be followed by the study doctor. After the subject is released from the hospital s/he will need to see the study doctor during regular post-operative visits. The study doctor will continue to check the wound. If the wound closes, s/he will see the study doctor 30 days later to have the closed wound checked.
Day of First Surgery:
3D images after the surgery with eKare Insight device
Tissue and bone samples - the doctor will take 2 small samples of tissue from the subject's wound before debridement (removal of dead or unhealthy tissue), and after debridement (clean margins) and 1 sample of bone before debridement in case of bone infection, and these tissue samples will be kept and tested for the amount and type of bacteria that are present (qPCR analysis/laboratory analysis).
Wound measurements after the surgery
The study doctor will decide if the subject still qualifies to be in the study
Randomization (like flipping a coin) to either Quantum™ NPWT with Irrigation or Quantum™ NPWT without Irrigation
Placement of therapy on the wound
Collection of current antibiotics
Collection of adverse event information
Daily Treatments (while in the hospital):
Collection of current antibiotics
Collection of adverse event information
This will take about 15 minutes.
Additional Surgery (if needed to remove dead tissue or to close the wound):
Tissue sample - the doctor will take 2 small samples of tissue from the subject's wound after debridement (clean margin), and these tissue samples will be kept and tested for the amount and type of bacteria that are present (qPCR analysis/laboratory analysis)
3D images of the wound after the surgery/debridement at bedside with eKare Insight device if the wound is still open
Wound measurements after the surgery/debridement at bedside
Wound closure or placement of therapy on the wound
Collect current antibiotics
Collect adverse event information
If the subject's wound is not closed upon hospital discharge, NPWT will continue at home without irrigation.
Home Health Visits If the subject continues to receive NPWT after hospital discharge, the subject will be seen twice weekly by a home health nurse for dressing changes. The home health nurse will collect sitting blood pressure and pulse rate. Amount, type and character of drainage will be documented, as well as any adverse events and changes to concomitant medications. Offloading will be reapplied after dressing changes.
Follow-Up Visits per standard of care (after therapy has stopped):
Dressing change / removal / Offloading
Wound measurements and infection assessment
Results of standard-of-care laboratory tests including a white blood cell count, blood chemistry (tests to see how well organs, such as the liver and kidneys are working), glycated hemoglobin, albumin, prealbumin, erythrocyte sedimentation rate, C-reactive protein and blood glucose.
3D image of the wound with eKare device (if indicated, if the wound is still open)
Collection of current antibiotics
Collection of adverse event information
These visits will take about 30 minutes.
End of Study - Wound Closure Follow-up Visit (30 days +/-7 days after your wound closes, if it closes within 12 weeks from Day of first surgery) or Week 16:
Closed wound assessment
For subjects whose wound has not closed:
3D images of the wound with eKare device Return to standard care
Collection of current antibiotics
Collection of adverse event information
SF-36 Questionnaire and other patient-reported outcomes questionnaires
This visit will take about 30 minutes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Foot Ulcer, Diabetic
Keywords
diabetic foot ulcer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Quantum™ Therapy/NPWT with Prontosan
Arm Type
Active Comparator
Arm Description
Quantum™ Negative Pressure Wound Therapy with Prontosan irrigant.
Arm Title
Quantum™ Therapy
Arm Type
Active Comparator
Arm Description
Quantum™ Negative Pressure Wound Therapy without irrigant.
Intervention Type
Device
Intervention Name(s)
Quantum™ Therapy - NPWT with Prontosan
Intervention Description
Negative pressure wound therapy with Prontosan irrigation.
Intervention Type
Device
Intervention Name(s)
Quantum™ Therapy
Intervention Description
Negative pressure wound therapy without irrigation.
Primary Outcome Measure Information:
Title
Compare clinical outcomes (time to wound healing, number of surgeries) with Negative Pressure Wound Therapy with irrigation and Negative Pressure Wound Therapy without irrigation.
Description
The investigators expect that patients treated with NPWT with irrigation will a have higher proportions of wounds that heal, fewer surgeries, and faster wound healing trajectories when compared to patients treated with traditional NPWT without irrigation.
Time Frame
Up to 12 weeks
Secondary Outcome Measure Information:
Title
Compare quantitative cultures (bacterial load as measured by qPCR) and number of clinical infections in patients treated with NPWT with irrigation compared to conventional NPWT.
Description
The investigators expect that patients treated with NPWT and irrigation will have a significantly lower bacterial load, and fewer and less severe clinical infections.
Time Frame
Up to 12 weeks
Other Pre-specified Outcome Measures:
Title
Compare responses to the HR-QOL questionnaires of patients treated with NPWT with irrigation compared to conventional NPWT.
Description
The investigators expect that patients treated with NPWT and continuous irrigation will have significantly higher indicators of functional health and well-being as compared with standard NPWT
Time Frame
Up to 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of diabetes mellitus
Men/women ≥21 years old
Foot or ankle wounds sized 5 cm2 -100 cm2
ABI≥0.5 or toe pressures >30 mmHg
Exclusion Criteria:
Active Charcot arthropathy
Unable to use NPWT at home
Untreated bone or soft tissue infection
Unable to keep research appointments
Active alcohol or substance abuse (> 14 drinks per week over the last 3 months) or substance abuse (current use of cocaine, heroine or methamphetamine or if drug or alcohol use will interfere with follow up visits in foot clinic in the opinion of the investigator)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lawrence A Lavery, DPM, MPH
Organizational Affiliation
UT Southwestern Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UT Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-9132
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Negative Pressure Wound Therapy as a Drug Delivery System (ADANPWT)
We'll reach out to this number within 24 hrs